COVID-19 Impacts on Pricing and Access

15:00
Chairperson’s Opening Remarks

Christine Kuan, Board Director, Taiwan Cognitive Enhancement Association, Taiwan

15:00
COVID-19 Response Dialogue: Accelerating Speed to Market, Drug Accessibility and Affordability

• Assessing regulator’s priority, managing delays and disruption on appraisals
• Not so new normal: Impediments to commercialising drugs at the same speed and scale
• Donation and pricing commitments from pharma manufacturers
• Developments in Government pricing and reimbursement
• How will pharma price the affordable therapeutics against COVID-19?

Moderator:
Alexander Zach, Senior Vice President , Global Head of Market Access , Policy and Pricing , Biocon Biologics Ltd

Panellists:
Yelitte Ho, Manager, Access and Funding Policy, Medicines Australia, Australia
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan
Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore

15:45
Managing the Effects of COVID-19 on Drug Access

• Propagating international access for drugs
• Improving access for high cost drugs – will it be the case for coronavirus treatments? -Creating innovative value
• Overcoming access difficulties in regions

Alexander Zach, Senior Vice President , Global Head of Market Access , Policy and Pricing , Biocon Biologics Ltd

16:15
Online Networking & Stretch Break

16:30
Agile Marketing in the era of COVID-19

• Redefine, transform and innovate pharma business strategy for greater access
• Adjusting commercial models- patient-physician relationships
• Catering to high population markets

Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan

17:00
Personalized Healthcare – Enabling a Next Generation Healthcare Ecosystem to Accelerate Patient Access in Singapore

Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore

17:30
Changing Regional Landscapes towards Digitalisation and what it means for Access

Reswita Gisriani, Chair of Cluster 1 Market Access Council, Medtronic, Indonesia

18:00
Chairperson’s Summary and End of Day 1

Agile Market Access

13:00
Chairperson’s Opening Remarks

Christine Kuan, Board Director, Taiwan Cognitive Enhancement Association, Taiwan

13:00
Dealing with COVID-19 and Drug Access in Indonesia

• Managing access and supply disruption for usual drugs
• Local in-ward looking policy trends and the impacts
• Prioritising local manufacturing and suppliers

Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

13:30
Shifting Mindsets: Increasing Access Sustainably in LMICs with Limited Public Funding

• Development of locally-tailored access solutions balancing access and sustainability
• Scaling innovative access approaches for specialized, high-cost treatments
• The role of multi-stakeholder partnerships in ensuring sustainability
• Facilitating the patient experience through digital tools
• Case study: Maximizing medical benefit through Patient Support Programs

Roshel Jayasundera, Director, Global Consulting, Axios International, Dubai

14:00
Fair Pricing and Drug Affordability Whilst Satisfying Governments Healthcare Policy  

• ASEAN and Asia market analysis
• Working with different reimbursement regimes – Aiming for a Win-Win situation
• Managing drug development costs, investments and ROIs
• Improving drug access and copayment- What is the right balance?
• Developed vs emerging market landscapes: What are the key considerations for growth

Moderator:
Jun Feng, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore  

Panellists:
Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
Judy Deng, Head of Market Access, Oncology, Novartis, China
Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia

14:55
Regenerative Medicine Part 1: Pricing and Market Access in Japan and SEA

Co-Presenters:
Neal Somchand, Principal and Head of Japan, Deallus Consulting, Tokyo
Phoebe Lam, Consultant, Deallus Consulting

15:25
Online Networking and Stretch Break

15:35
China’s Drug Landscape – The Medical Insurance Reform of Tripartite System and Implications for Market Access

• Access for innovative therapies in China
• Practical considerations and negotiations for placement onto the list of National Reimbursement Drug List (NRDL)
• Proving value for innovative therapies and medical insurance
• China case study: Managing access for cancer drugs post COVID-19 outbreak

Judy Deng, Head of Market Access, Oncology, Novartis, China

16:00
Regenerative Medicine Part 2: Pricing and Market Access in Australia and China

Co-Presenters:
Helen Cunliffe, Senior Consultant and Australia Lead, Deallus Consulting, Australia
Flora Tian, China Office Lead, Deallus Consulting, Shanghai

16:30
Oncology and COVID-19: Challenges and Opportunities

• Building access to cancer care in emerging markets
• Building portfolio and connecting with customers
• Using digital tools and access strategies

Anupama Rao Singh, Business Head – LATAM | Head – Oncology and Institutional Business COE, Dr.Reddy’s Emerging Markets

17:00
Chairperson’s Summary and End of Day 2

Payer and Reimbursement

13:00
Chairperson’s Opening Remarks

Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan

13:00
Case Study:
Lundbeck’s Value Creation Strategies in Asia 

• Working with payers, patients and reimbursement bodies for creating customer-focused values
• Value creation for disease area of psychiatry
• Lowering stigma for treatments in neurology and psychiatry

 Viviendouf Koh, Regional Marketing Director, South and East Asia, Lundbeck, Singapore

13:30
Australia Case Study:
COVID-19 Government, Reimbursement & Regulatory Updates 

• COVID-19 in Australia
• Universal access to healthcare in Australia and the Pharmaceutical Benefits Scheme (PBS)
• Universal Subsidy Scheme for Medicines
• How does a drug get listed on the PBS (registration process, pricing, listing consideration)?
• Key factors influencing decision making by the independent Pharmaceutical Benefits Advisory Committee
• Patent and data protection of pharmaceuticals in Australia

Yelitte Ho, Manager, Access and Funding Policy, Medicines Australia, Australia

Optimising RWE and HTA         

14:00
Demonstrating Value and Data Gathering for RWE in Asia

• Understand how RWE is different from randomized control trials (RCTs)
• How do Regulatory bodies consider the use of RWE for decision making?
• Challenges to collect RWE; how to access and when to use do we have that ready in Asia
• Successful regional case studies

Kim Soyoung, Director HEOR, Medical Affairs, Asia & Oceania, Astellas Pharma, Singapore

14:30
Online Networking and Stretch Break

15:00
Use of Real-World Evidence in the Drug Registration Process 

• What’s real World Data, Real world Evidence?
• How is Real World Evidence generated?
• Overview of Regulations (US FDA, EMA, China NMPA)

Gaelle Richer, Director Global Regulatory Affairs, GSK, Singapore

15:30
HTA for Growing Economies

• Challenges and Opportunities of using HTA
• Key areas of focus for emerging markets
• Maximising the returns of HTA on proving drug value

Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia

16:00
Online Networking and Stretch Break

Diversity and Inclusion in Pharma

16:20
Cultivating the Next-Gen of Women Leaders in Pharma

• Why does gender equality matter on the board?
• Key challenges facing women leaders in Pharma
• Management efforts to address some of these challenges, and remaining gaps
• Reflections on the journey to the top
• Breaking the glass ceiling: Lessons learnt along the way, and advice to my younger self
• Management efforts to address some of these challenges, and remaining gaps

Moderator:
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan

Panelists:
Anupama Rao Singh, Business Head – LATAM | Head – Oncology and Institutional Business COE, Dr.Reddy’s Emerging Markets, Dr Reddys, India
Angela Brady, Director of Innovation Research, APAC R&D, GSK, Singapore
Chandana Yeluri, Head- Digital and Continuous Improvement, Sandoz Development Center, Novartis, India
More panelists to be confirmed

17:10
End of Digital Conference Day 3